Member Info for daveycaferacer

All time low today, lowest in 9 years, shareholder value decimated and all for nothing

yes smell, for the Directors, especially the CEO, bearing in mind he is so bullish on the Company's prospects

The last time the Directors bought shares in the market was 2015, maybe they'd like to make a purchase now to show the market they have confidence in the Company?

It does seem that if the balance of trades continues in such a fashion a suspension could happen, possibly at the request of the Company. Hopefully it will start to pickup if we get some positive news.

and that'll be a typical AIM placing that will be forward sold, shocking. The Company should carry out an urgent strategic review. If it cannot turn any of its assets into revenue producing assets it really should consider disposals.

Despite recent setbacks amones, I think this article is also a useful reminder about the potential here, especially with regards to the biggest prize, which is Savolitinib in NSCLC

https://www.standard.co.uk/business/anthony-hilton-the-remarkable-tale-of-chimed-s-growth-a3661656.html

excellent, thankyou amones, and we of course have the Savolitinib + Tagrisso combination in NSCLC to look forward to. This has predicted peak sales of $1.5bn in the global market and also the Exon 14 del in China of $239m. IF we were to get these launched by 2021/2022 they would be huge with the royalties converting to net income of circa $330m p.a - just think what that will do to our valuation!

I continue to Buy.

https://docs.wixstatic.com/ugd/07354c_ceb68a957be94a39a937b752216bddf4.pdf

For anyone interested, you can sign up to TD's Healthcare research alerts on their website.

what was the size? 200 quid!?

Great post Maru, good luck to you with your future investments. With regards to value investing it seems to me that Chi-Med offers great value at times followed by periods where it over-extends itself. Nice linear growth would be welcome!

https://stocksnewsfeed.com/benzinga/chi-med-highlights-preliminary-phase-ii-savolitinib-imfinzi-combination-data-in-advanced-papillary-renal-cell-carcinoma-at-2019-asco-genitourinary-cancers-symposium/?utm_source=dlvr.it&utm_medium=twitter

https://meetinglibrary.asco.org/record/169449/abstract

A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO).

Being presented at ASCO GU19 today

I took it from this

Krane Funds Advisors LLC,has filed Form 13F for Q4 2018.Opened NEW positions in $JG $BILI $GDS $HCM $HUYA $JKS $KWEB $PPDF $PDD $TME

https://fintel.io/i/krane-funds-advisors

I struggle to take Louis too seriously - someone needs to tell him it is no longer Movember

kiboooom........this could hit 1p

Following HCM on some U.S Bulletin Boards there are daily updates detailing mutual funds and ETF's taking positions in Chi-Med - the latest is KMED

https://kraneshares.com/kraneshares-expands-healthcare-suite-with-launch-of-emerging-markets-healthcare-etf-nyse-kmed/

Wondering if we get gift aid on our investment in Kibo, I mean, we have built a school in the bush, so that's charity.

ASCO GH19 currently underway in SF

CALYSPO Poster session https://meetinglibrary.asco.org/record/170233/abstract

Unfortunately I cannot see any Investors putting up any more cash by way of a placing. The company's track record is simply not good enough for a placing to be viable. Advisors will probably make that advise to the Board.

I'm making further purchases, I wonder if miti, who sold out at the top has taken another position. I have always been buying but I did take a pause after the recent setbacks. The market appears to have taken stock and recognised the potential. The Company's push on the GLOBAL side may have been picked up as positive. I also think the positive noises coming out of the U.S - China trade talks is helping anything with a China link.